<p>Nuveen LLC 在第一季度收購了強生（NYSE:JNJ - 免費報告）股票的新頭寸，根據其最近向證券交易委員會（SEC）提交的文件。這家機構投資者收購了 8,256,079 股該公司的股票，估值約為 13,691,880,000 美元。Nuveen LLC 在最近的報告期末持有強生約 0.34% 的股份。</p>
<p>獲取 <strong>強生</strong> 的提醒：</p>
<ul>
<li>3 大高分紅股票，強勁盈利支撐</li>
</ul>
<p>其他幾家機構投資者最近也增加或減少了在該公司的持股。先鋒集團（Vanguard Group Inc.）在第一季度將其在強生的持股提高了 0.5%。先鋒集團目前持有 233,962,679 股該公司的股票，估值為 38,800,371,000 美元，在上個季度又購買了 1,170,120 股。北方信託公司（Northern Trust Corp）在第四季度將其在強生的持股提高了 12.3%。北方信託公司目前持有 30,813,175 股該公司的股票，價值 4,456,201,000 美元，在上個季度又購買了 3,363,235 股。紐約梅隆銀行（Bank of New York Mellon Corp）在第一季度將其在強生的持股增加了 26.4%。紐約梅隆銀行目前持有 23,182,464 股該公司的股票，價值 3,844,580,000 美元，在此期間又購買了 4,842,582 股。查爾斯·施瓦布投資管理公司（Charles Schwab Investment Management Inc.）在第一季度將其在強生的持股增加了 3.9%。查爾斯·施瓦布投資管理公司目前持有 18,899,263 股該公司的股票，估值為 3,133,602,000 美元，在此期間又購買了 712,181 股。最後，馬薩諸塞金融服務公司（Massachusetts Financial Services Co. MA）在第一季度將其在強生的持股增加了 2.5%。馬薩諸塞金融服務公司目前持有 18,282,410 股該公司的股票，估值為 3,031,955,000 美元，在此期間又購買了 448,666 股。69.55% 的股票由機構投資者持有。</p>
<h2>強生股票表現</h2>
<p>強生（NYSE JNJ）週五開盤價為 173.40 美元。強生的 1 年最低價為 140.68 美元，1 年最高價為 173.96 美元。該公司的 50 日簡單移動平均線為 159.26 美元，200 日簡單移動平均線為 157.52 美元。公司的流動比率為 1.01，速動比率為 0.76，債務與股本比率為 0.50。該公司的市值為 4176.1 億美元，市盈率為 18.55，市盈增長比率為 2.21，貝塔值為 0.41。</p>
<ul>
<li>擔心反彈消退？考慮這 3 只分紅股票</li>
</ul>
<p>強生（NYSE:JNJ - 獲取免費報告）最近於 7 月 16 日（星期三）公佈了季度財報。公司報告每股收益（EPS）為 2.77 美元，超出市場共識預期的 2.68 美元，超出 0.09 美元。強生的淨利潤率為 25.00%，股本回報率為 32.49%。公司本季度的收入為 237.4 億美元，而分析師預期為 228.5 億美元。去年同期，公司每股收益為 2.82 美元。公司的收入同比增長了 5.8%。整體來看，研究分析師預計強生在當前財政年度的每股收益將達到 10.58 美元。</p>
<h2>強生宣佈分紅</h2>
<p>該公司最近還宣佈了季度分紅，將於 9 月 9 日（星期二）支付。8 月 26 日（星期二）的股東將獲得每股 1.30 美元的分紅。這相當於每年 5.20 美元的分紅，分紅收益率為 3.0%。除息日為 8 月 26 日（星期二）。強生的派息比率為 55.61%。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>4 大主要股票上調 2025 年指引，分析師目標上升</li>
</ul>
<p>一些分析師最近對該公司發佈了報告。巴克萊（Barclays）將強生的目標價從 165.00 美元上調至 176.00 美元，並在 7 月 17 日的研究報告中給予該股票 “持平” 評級。雷蒙德·詹姆斯金融（Raymond James Financial）將強生的目標價從 165.00 美元下調至 162.00 美元，並在 4 月 14 日的研究報告中對該股票給予 “跑贏大盤” 評級。Leerink Partners 將強生的評級從 “跑贏大盤” 下調至 “市場表現”，並在 5 月 13 日的研究報告中將該股票的目標價從 169.00 美元下調至 153.00 美元。派珀·桑德勒（Piper Sandler）在 7 月 17 日的研究報告中重申了對強生股票的 “增持” 評級。最後，美國銀行（Bank of America）將強生股票的目標價從 161.00 美元上調至 175.00 美元，並在 7 月 17 日的報告中給予該股票 “中性” 評級。九位股票研究分析師對該股票給予了持有評級，十位給予了買入評級，兩位給予了強烈買入評級。根據 MarketBeat.com 的數據，強生目前的共識評級為 “適度買入”，共識目標價為 174.50 美元。</p>
<p><strong>閲讀我們對 JNJ 的最新分析</strong></p>
<h2>強生公司簡介</h2>
<p>（免費報告）</p>
<p>強生是一家控股公司，專注於醫療領域的產品研究、開發、製造和銷售。它通過創新藥物和醫療科技兩個部門運營。創新藥物部門專注於免疫學、傳染病、神經科學、腫瘤學、心血管和代謝以及肺動脈高壓。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過強生</li>
<li>消費者物價指數測量什麼？</li>
<li>火箭實驗室報告第二季度業績：牛市論點是否依然成立？</li>
<li>基礎材料股票投資</li>
<li>特朗普 GLP-1 試點計劃可能推動諾和諾德和禮來</li>
<li>航空公司股票 - 現在值得購買的頂級航空公司股票</li>
<li>現在是購買 Cheniere Energy 的好時機：預計將創下新高</li>
</ul>
<p><strong>想知道其他對沖基金持有的強生股票嗎？</strong> 請訪問 HoldingsChannel.com 獲取強生（NYSE:JNJ - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在強生嗎？</h2>
<p>在考慮強生之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而強生並不在名單上。</p>
<p>雖然強生目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

強生

<p>Nuveen LLC 在第一季度收購了強生（NYSE: JNJ）的新股份，購買了 8,256,079 股，價值約為 13.7 億美元。這次收購使 Nuveen 的持股比例達到公司總股份的約 0.34%。其他機構投資者，包括先鋒集團和北方信託，也增加了在強生的持股。該股票目前的交易價格為 173.40 美元，市值為 4176.1 億美元，股息收益率為 3.0%</p>

<p>Nuveen LLC acquired a new position in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,256,079 shares of the company's stock, valued at approximately $1,369,188,000. Nuveen LLC owned approximately 0.34% of Johnson &amp; Johnson at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Nuveen LLC 在第一季度收購了強生（NYSE:JNJ - 免費報告）股票的新頭寸，根據其最近向證券交易委員會（SEC）提交的文件。這家機構投資者收購了 8,256,079 股該公司的股票，估值約為 13,691,880,000 美元。Nuveen LLC 在最近的報告期末持有強生約 0.34% 的股份。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>強生</strong> 的提醒：</p>
</div><ul>
<li>3 Big Dividend Plays With Strong Earnings to Back Them</li>
</ul>
<div class="lb-trans"><ul>
<li>3 大高分紅股票，強勁盈利支撐</li>
</ul>
</div><p>Several other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Johnson &amp; Johnson by 0.5% in the first quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company's stock valued at $38,800,371,000 after buying an additional 1,170,120 shares during the last quarter. Northern Trust Corp boosted its position in shares of Johnson &amp; Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after purchasing an additional 3,363,235 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Johnson &amp; Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after buying an additional 4,842,582 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Johnson &amp; Johnson by 3.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company's stock valued at $3,133,602,000 after purchasing an additional 712,181 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Johnson &amp; Johnson by 2.5% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company's stock valued at $3,031,955,000 after buying an additional 448,666 shares during the period. 69.55% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他幾家機構投資者最近也增加或減少了在該公司的持股。先鋒集團（Vanguard Group Inc.）在第一季度將其在強生的持股提高了 0.5%。先鋒集團目前持有 233,962,679 股該公司的股票，估值為 38,800,371,000 美元，在上個季度又購買了 1,170,120 股。北方信託公司（Northern Trust Corp）在第四季度將其在強生的持股提高了 12.3%。北方信託公司目前持有 30,813,175 股該公司的股票，價值 4,456,201,000 美元，在上個季度又購買了 3,363,235 股。紐約梅隆銀行（Bank of New York Mellon Corp）在第一季度將其在強生的持股增加了 26.4%。紐約梅隆銀行目前持有 23,182,464 股該公司的股票，價值 3,844,580,000 美元，在此期間又購買了 4,842,582 股。查爾斯·施瓦布投資管理公司（Charles Schwab Investment Management Inc.）在第一季度將其在強生的持股增加了 3.9%。查爾斯·施瓦布投資管理公司目前持有 18,899,263 股該公司的股票，估值為 3,133,602,000 美元，在此期間又購買了 712,181 股。最後，馬薩諸塞金融服務公司（Massachusetts Financial Services Co. MA）在第一季度將其在強生的持股增加了 2.5%。馬薩諸塞金融服務公司目前持有 18,282,410 股該公司的股票，估值為 3,031,955,000 美元，在此期間又購買了 448,666 股。69.55% 的股票由機構投資者持有。</p>
</div><h2>Johnson &amp; Johnson Stock Performance</h2>
<div class="lb-trans"><h2>強生股票表現</h2>
</div><p>NYSE JNJ opened at $173.40 on Friday. Johnson &amp; Johnson has a 1 year low of $140.68 and a 1 year high of $173.96. The firm's 50 day simple moving average is $159.26 and its 200 day simple moving average is $157.52. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $417.61 billion, a price-to-earnings ratio of 18.55, a P/E/G ratio of 2.21 and a beta of 0.41.</p>
<div class="lb-trans"><p>強生（NYSE JNJ）週五開盤價為 173.40 美元。強生的 1 年最低價為 140.68 美元，1 年最高價為 173.96 美元。該公司的 50 日簡單移動平均線為 159.26 美元，200 日簡單移動平均線為 157.52 美元。公司的流動比率為 1.01，速動比率為 0.76，債務與股本比率為 0.50。該公司的市值為 4176.1 億美元，市盈率為 18.55，市盈增長比率為 2.21，貝塔值為 0.41。</p>
</div><ul>
<li>Worried About a Fading Rally? Consider These 3 Dividend Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>擔心反彈消退？考慮這 3 只分紅股票</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson &amp; Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period in the previous year, the firm posted $2.82 EPS. The firm's revenue was up 5.8% on a year-over-year basis. As a group, research analysts expect that Johnson &amp; Johnson will post 10.58 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>強生（NYSE:JNJ - 獲取免費報告）最近於 7 月 16 日（星期三）公佈了季度財報。公司報告每股收益（EPS）為 2.77 美元，超出市場共識預期的 2.68 美元，超出 0.09 美元。強生的淨利潤率為 25.00%，股本回報率為 32.49%。公司本季度的收入為 237.4 億美元，而分析師預期為 228.5 億美元。去年同期，公司每股收益為 2.82 美元。公司的收入同比增長了 5.8%。整體來看，研究分析師預計強生在當前財政年度的每股收益將達到 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Announces Dividend</h2>
<div class="lb-trans"><h2>強生宣佈分紅</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Tuesday, August 26th. Johnson &amp; Johnson's payout ratio is 55.61%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了季度分紅，將於 9 月 9 日（星期二）支付。8 月 26 日（星期二）的股東將獲得每股 1.30 美元的分紅。這相當於每年 5.20 美元的分紅，分紅收益率為 3.0%。除息日為 8 月 26 日（星期二）。強生的派息比率為 55.61%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise</li>
</ul>
<div class="lb-trans"><ul>
<li>4 大主要股票上調 2025 年指引，分析師目標上升</li>
</ul>
</div><p>A number of analysts recently issued reports on the company. Barclays increased their target price on Johnson &amp; Johnson from $165.00 to $176.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Thursday, July 17th. Raymond James Financial lowered their target price on Johnson &amp; Johnson from $165.00 to $162.00 and set an &#34;outperform&#34; rating on the stock in a research report on Monday, April 14th. Leerink Partners lowered shares of Johnson &amp; Johnson from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and dropped their price target for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Piper Sandler reaffirmed an &#34;overweight&#34; rating on shares of Johnson &amp; Johnson in a research report on Thursday, July 17th. Finally, Bank of America lifted their target price on shares of Johnson &amp; Johnson from $161.00 to $175.00 and gave the stock a &#34;neutral&#34; rating in a report on Thursday, July 17th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Johnson &amp; Johnson currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $174.50.</p>
<div class="lb-trans"><p>一些分析師最近對該公司發佈了報告。巴克萊（Barclays）將強生的目標價從 165.00 美元上調至 176.00 美元，並在 7 月 17 日的研究報告中給予該股票 “持平” 評級。雷蒙德·詹姆斯金融（Raymond James Financial）將強生的目標價從 165.00 美元下調至 162.00 美元，並在 4 月 14 日的研究報告中對該股票給予 “跑贏大盤” 評級。Leerink Partners 將強生的評級從 “跑贏大盤” 下調至 “市場表現”，並在 5 月 13 日的研究報告中將該股票的目標價從 169.00 美元下調至 153.00 美元。派珀·桑德勒（Piper Sandler）在 7 月 17 日的研究報告中重申了對強生股票的 “增持” 評級。最後，美國銀行（Bank of America）將強生股票的目標價從 161.00 美元上調至 175.00 美元，並在 7 月 17 日的報告中給予該股票 “中性” 評級。九位股票研究分析師對該股票給予了持有評級，十位給予了買入評級，兩位給予了強烈買入評級。根據 MarketBeat.com 的數據，強生目前的共識評級為 “適度買入”，共識目標價為 174.50 美元。</p>
</div><p><strong>Read Our Latest Analysis on JNJ</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 JNJ 的最新分析</strong></p>
</div><h2>Johnson &amp; Johnson Company Profile</h2>
<div class="lb-trans"><h2>強生公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>強生是一家控股公司，專注於醫療領域的產品研究、開發、製造和銷售。它通過創新藥物和醫療科技兩個部門運營。創新藥物部門專注於免疫學、傳染病、神經科學、腫瘤學、心血管和代謝以及肺動脈高壓。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>What does consumer price index measure?</li>
<li>Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?</li>
<li>Basic Materials Stocks Investing</li>
<li>Trump GLP-1 Pilot Program Could Boost Novo Nordisk &amp; Eli Lilly</li>
<li>Airline Stocks - Top Airline Stocks to Buy Now</li>
<li>Now Is a Great Time to Buy Cheniere Energy: New High Expected</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過強生</li>
<li>消費者物價指數測量什麼？</li>
<li>火箭實驗室報告第二季度業績：牛市論點是否依然成立？</li>
<li>基礎材料股票投資</li>
<li>特朗普 GLP-1 試點計劃可能推動諾和諾德和禮來</li>
<li>航空公司股票 - 現在值得購買的頂級航空公司股票</li>
<li>現在是購買 Cheniere Energy 的好時機：預計將創下新高</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他對沖基金持有的強生股票嗎？</strong> 請訪問 HoldingsChannel.com 獲取強生（NYSE:JNJ - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在強生嗎？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮強生之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而強生並不在名單上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然強生目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Nuveen LLC 購入了強生公司（NYSE: JNJ）的新股份